RCUS Q3 2025 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M-45.8% YoY

Gross Profit

$24M92.3% margin

Operating Income

-$142M-546.2% margin

Net Income

-$135M-519.2% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

-83.8%

Cash Flow

Operating Cash Flow

-$97M

Free Cash Flow

-$97M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$974M

Total Liabilities

$538M

Stockholders' Equity

$436M

Cash & Equivalents

$238M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$48M	-45.8%
Gross Profit	$24M	$48M	-50.0%
Operating Income	-$142M	-$105M	-35.2%
Net Income	-$135M	-$92M	-46.7%

Revenue Segments

License And R&D Services

$192M92%

R&D Services

$17M8%